RxDoctor Payments Data

Bryan Blare

Optometrist · Mesa, AZNPI 1063409548

Payments from drug & device makers

$3,750in general payments, 2019–2025

Across 125 payments — averaging $30.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$795
  • Glaukos Corporation$319
  • Harrow Eye, LLC$308
  • Bausch & Lomb Americas Inc.$299
  • Alcon$269
  • Biotissue Holdings Inc.$252
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$1504%
  • Food & beverage$3,58195%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,750 in reported general payments places this provider in the 85th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$38,272
Medicare patients
154
Services billed
424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine358$242,649
MieboPerfluorohexyloctane/Pf93$72,111
LumiganBimatoprost66$34,360
XiidraLifitegrast37$29,121
XdemvyLotilaner11$21,072
RocklatanNetarsudil Mesylat/Latanoprost27$9,121
VyzultaLatanoprostene Bunod20$9,104
Cyclosporine23$7,398
SimbrinzaBrinzolamide/Brimonidine Tart27$7,171
CombiganBrimonidine Tartrate/Timolol18$5,571
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$4,383
Travoprost11$1,238
Fluorometholone13$1,215
Prednisolone Acetate15$729
Latanoprost70$517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$795$282,580442 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$299$110,337150 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$219$21,07211 claims
AlconSimbrinza$269$7,17127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →